Barclays
AQST icon

Barclays’s Aquestive Therapeutics AQST Stock Holding History

Barclays’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.15M Buy
996,665
+197,502
+25% +$831K ﹤0.01% 1943
2026
Q1 		$3.32M Buy
799,163
+458,356
+134% +$1.86M ﹤0.01% 2061
2025
Q4 		$2.2M Buy
340,807
+209,049
+159% +$1.3M ﹤0.01% 2866
2025
Q3 		$737K Sell
131,758
-22,070
-14% -$95.4K ﹤0.01% 3562
2025
Q2 		$509K Buy
153,828
+70,871
+85% +$203K ﹤0.01% 3751
2025
Q1 		$241K Sell
82,957
-35,754
-30% -$108K ﹤0.01% 3939
2024
Q4 		$423K Buy
118,711
+19,399
+20% +$89.5K ﹤0.01% 3932
2024
Q3 		$495K Buy
99,312
+73,542
+285% +$286K ﹤0.01% 3780
2024
Q2 		$67K Buy
+25,770
New +$86.1K ﹤0.01% 4089
2023
Q4 		– Sell
-7,144
Closed -$10.9K – 5221
2023
Q3 		$10.9K Buy
+7,144
New +$12.3K ﹤0.01% 4289
2022
Q2 		– Sell
-24,829
Closed -$65K – 5007
2022
Q1 		$65K Hold
24,829
– – ﹤0.01% 3992
2021
Q4 		$97K Sell
24,829
-3,097
-11% -$15.5K ﹤0.01% 3738
2021
Q3 		$122K Sell
27,926
-3,456
-11% -$13.6K ﹤0.01% 3829
2021
Q2 		$125K Buy
31,382
+14,770
+89% +$59K ﹤0.01% 3755
2021
Q1 		$86K Buy
16,612
+10,197
+159% +$54.2K ﹤0.01% 4062
2020
Q4 		$34K Sell
6,415
-2,665
-29% -$16K ﹤0.01% 4554
2020
Q3 		$43K Sell
9,080
-23,262
-72% -$152K ﹤0.01% 4664
2020
Q2 		$156K Buy
+32,342
New +$149K ﹤0.01% 4246
2020
Q1 		– Sell
-159
Closed -$1K – 6118
2019
Q4 		$1K Sell
159
-652
-80% -$3.39K ﹤0.01% 6264
2019
Q3 		$2K Buy
811
+391
+93% +$1.47K ﹤0.01% 6537
2019
Q2 		$2K Sell
420
-5,441
-93% -$27.9K ﹤0.01% 6787
2019
Q1 		$40K Buy
+5,861
New +$41.1K ﹤0.01% 6023
2018
Q4 		– Sell
-1,956
Closed -$34K – 6907
2018
Q3 		$34K Buy
+1,956
New +$32.2K ﹤0.01% 6262

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Barclays's AQST Position: Q2 2026 in Review

Barclays increased its Aquestive Therapeutics (AQST) stake by 25% in Q2 2026, buying an estimated $831K and bringing the position to 996,665 shares worth $4.15M. The position accounts for ﹤0.01% of the portfolio, ranked #1943.

Barclays first reported a position in AQST in Q3 2018 and has held it in 23 quarters since. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Barclays held 996,665 shares of Aquestive Therapeutics worth $4.15M as of Q2 2026.
  • Barclays bought 197,502 Aquestive Therapeutics shares in Q2 2026, an estimated $831K.
  • Aquestive Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1943 holding.
  • Barclays first reported a position in Aquestive Therapeutics in Q3 2018 and has held it in 23 quarters since.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.